Media Coverage

Ceva adds to antiparasitics patent portfolio

Feb 23, 2017 - Animal Pharm

By Richard Nicholas
Animal Pharm
February 23, 2017

The first month of 2017 saw the publication of new patent applications on novel antiparasitic combinations, as well as a variety of new technologies for vaccines and veterinary medicines.

According to the Animal Pharm Patent Archive, firms with applications published in January included Bayer Animal Health, Biogénesis Bagó, Ceva Santé Animale, Merck Animal Health (Intervet), Merial, Virbac and Zoetis.


In WO2017009219 Ceva claims the use of a combination of antiparasitics to control the spread of heartworm disease by administering the combination to one or more infested animals in a group.

The combination is composed of a neonicotinoid and a pyrethroid, preferably dinotefuran and permethrin, respectively. Additionally, an insect growth regulator such as pyriproxyfen, and a macrocyclic lactone such as milbemycin oxime may also be included. The inventors suggest the combination can overcome the limitations of existing treatments, by targeting the propagation of the disease by mosquitoes.

Recently, data from a Ceva-sponsored investigation has been presented to back a 'double defense' strategy against heartworm in dogs. In the study, Ceva's Vectra 3D topical parasiticide to control mosquitoes provided an additional layer of protection when used with a heartworm preventative.

In EP3120846 Ceva claims a novel combination of antiparasitics for controlling fleas and ticks on cats and dogs. The combination of a neonicotinoid and an N-arylpyrazole, specifically dinotefuran and fipronil, respectively, is for topical use as a spot-on, a pour-on or a line-on.

In November 2016, Ceva launched Catego for cats on the US market. The company said it was the first fast-acting topical flea and tick treatment specifically for cats and contains dinotefuran, fipronil and pyriproxyfen.

Two applications from Bayer CropScience were of potential veterinary interest. In WO2017005717 Bayer claims a new series of thiadiazole compounds for use in controlling arthropod parasites on animals. While in WO2017005673 it claims new nitrogen heterocycle compounds for controlling pests. In both cases, activity against veterinary and agricultural pests is disclosed.


In WO2017001469 Ceva claims a new vector for vaccinating poultry based on an attenuated duck enteritis virus. Specifically, the virus has an inactivated UL4 gene, creating a vector that unlike the wild-type virus can be used in chicks younger than three days or in ovo.

A foreign gene, for example the VP2 protein of infectious bursal disease virus or the hemagglutinin protein of an influenza virus, may be inserted into the virus vector.

Duck enteritis virus does not naturally infect chickens, but the inventors found that administration of wild-type virus to one day old chicks or in ovo caused extensive death.

In WO2017015252 Zoetis claims novel liposomal adjuvants for delivering vaccine antigens. In particular, the liposomes are free of saponins, which have been implicated in the occurrence of transient fever and a drop in milk yield drop in lactating cows.

The liposomes may additionally contain immunostimulatory oligonucleotides, and the inventors claim use with a variety of antigens including bovine viral diarrhea virus, swine influenza virus and Eimeria profilin.

Other Pharmaceuticals

In WO2017013623 Biogénesis Bagó claims a method to increase both the quantity and quality of meat of female ruminants, particularly bovines, by administering high concentrations of progesterone for prolonged periods of time (30-120 days) via an intravaginal device.

Intravaginal delivery of progesterone is commonly used to synchronize estrus in ruminants prior to artificial insemination or natural mating, in which case the progesterone is administered for relatively short periods of time (7-12 days). 

The inventors disclose that estrus suppression using slow-release progesterone has a direct impact on animal behavior and welfare which is reflected in shortened periods of feeding, more weight gain and better carcass quality.

In three applications – WO2017005764WO2017005766 and WO2017005759 – Intervet claims new methods and intermediates for preparing CRTH2 antagonists.

Antagonists of the prostaglandin D2 receptor, CRTH2, have potential in humans for the treatment of allergic and other inflammatory diseases, and are being considered for use in treating canine atopic dermatitis.

In WO2017013167 Intervet claims a new formulation and manufacturing process for the anabolic growth promoter zilpaterol. By preparing a supersaturated solution of zilpaterol in a propylene glycol/water vehicle a feed premix was produced which overcame issues of non-uniform zilpaterol distribution in medicated feeds, particularly at lower concentrations.


In US2017023570 Merial claims an improved method of virus quantification. The method involves infecting cells with a diluted sample of the virus, and determining the number of infected cells by detecting a viral protein with a fluorescently-labelled antibody. The detection is carried out in 96-well pates using a personal image cytometer, specifically the CellInsight imager produced by ThermoFisher. Image cytometers combine the functions of a digital microscope, an image cytometer and a cell counter and capture cellular and subcellular image data and analyze the results.

According to the inventors, the new rapid methodology reduces the number of dilutions and duplicates necessary to accurately calculate the virus titer.

In US2017006894 Virbac claims a new flavored chewable composition for presenting a pharmaceutical ingredient to an animal.

The inventors found that combining a wetting agent such as glycerin, with a flowable, non-miscible oil, such as vegetable or soybean oil, makes it possible to obtain a chew that is stable, of a desirable consistency, and easy to manufacture and package.

 Reprinted with permission of Animal Pharm News




News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum